OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cookson on Understanding Predictive Features in the Management of Prostate Cancer

March 15th 2023

Michael S. Cookson, MD, MMHC, discusses how understanding the relationship between key predictive factors and disease progression can help better inform the overall management of prostate cancer.

Dr. Cohen on the Use of CAR T-cell Therapy in Earlier Lines of Multiple Myeloma Treatment

March 15th 2023

Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.

Dr. Santos on the Current Treatment Landscape in Squamous Cell Carcinoma of the Lung

March 15th 2023

Edgardo S. Santos, MD, FACP, discusses the current treatment landscape for patients with squamous cell carcinoma of the lung.

Dr. Phillips on BTK Inhibitor Selection in MCL

March 15th 2023

Tycel Phillips, MD, MPH, discusses how to approach selecting BTK inhibitors for patients with mantle cell lymphoma and treatment decisions following disease progression on a BTK inhibitor.

Dr. Sharma on Optimal Systemic Therapy for Early-Stage TNBC

March 15th 2023

Priyanka Sharma, MD, discusses updates in optimal systemic therapy strategies in early-stage triple-negative breast cancer.

Dr. Dalal on Graft Failure in Pediatric Non-malignant Disorders

March 15th 2023

Mansi Dalal, MD, discusses findings from a study investigating graft failure risk factors in pediatric patients receiving allogeneic hematopoietic stem cell transplant for non-malignant disorders.

Dr. Milner on Hematopoietic Stem Cell Transplant in Aplastic Anemia

March 15th 2023

Jordan B. Milner, MD, discusses findings from a study evaluating the use of hematopoietic stem cell transplant up front or as salvage therapy after unsuccessful immunosuppressive therapy in pediatric patients with severe aplastic anemia.

Dr. Patel on the Association Between Ki-67 and Race in Early Breast Cancer

March 14th 2023

Rima Patel, MD, discusses the associations between the 21-gene oncotype DX recurrence score, Ki-67, and race in early-stage breast cancer.

Dr. D'Ambrosio on the Rationale of Accelerated Partial Breast Irradiation in HR+ Breast Cancer

March 14th 2023

David D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.

Dr. Rimm on the Use of Multiplex Spatial Proteomic Profiling in Breast Cancer

March 14th 2023

David Rimm, MD, PhD, discusses both the use and advantages of utilizing multiplex spatial proteomic profiling in breast cancer.

Dr. Goy on the Management of Patients With Genetic Abnormalities and Low Risk in MCL

March 14th 2023

Andre H. Goy, MD, discusses the appropriate monitoring and management of patients with mantle cell lymphoma who display genetic abnormalities but are not considered to be high risk.

Dr. Harding on the Management of Immune-related AEs in Advanced Biliary Tract Cancer

March 14th 2023

James Harding, MD, discusses the management of immune-related adverse effects in patients with advanced biliary tract cancer.

Dr. Rampal on the Role of JAK Inhibitors in Myelofibrosis

March 14th 2023

Raajit K. Rampal, MD, PhD, discusses how the role of JAK inhibitors will continue to evolve in the treatment of patients with myelofibrosis.

Dr. Sauter on the Potential Role of BTK Inhibitors in Frontline CNS Lymphoma

March 14th 2023

Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.

Dr. Richardson on Proteasome Inhibitor/Monoclonal Antibody Combinations in Myeloma

March 14th 2023

Paul G. Richardson, MD, discusses the impact of combining proteasome inhibitors and monoclonal antibodies in multiple myeloma.

Dr. Iagaru on Advancements in PSMA-PET Imaging for Prostate Cancer

March 13th 2023

Andrei H. Iagaru, MD, discusses key points from his presentation on the use of novel vs conventional imaging to manage metastatic hormone-sensitive prostate cancer.

Dr. Hwang on First-line Treatment Options in HCC

March 13th 2023

Jimmy Hwang, MD, discusses currently available first-line treatment options in hepatocellular carcinoma, and areas of continued unmet need in this space.

Dr. Goy on Different Presentations of MCL

March 13th 2023

Andre H. Goy, MD, discusses differentiating between disease presentations in mantle cell lymphoma.

Dr. Calais on the Role of PSMA-PET Imaging in mCRPC

March 10th 2023

Jeremie Calais, MD, MSc, discusses the role of prostate-specific membrane antigen-PET imaging in metastatic-castrate resistant prostate cancer, and touches on the importance of integrating PSMA-PET imaging into community settings for clinical practice.

Dr. Dorff on the Continued Investigation of Upfront Chemotherapy in mHSPC

March 10th 2023

Tanya Dorff, MD, discusses key data supporting the use of intensified triplet regimens in metastatic hormone-sensitive prostate cancer, and remaining questions regarding the role of chemotherapy agents in these combinations.